Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018

SIMPLE SUMMARY: Multiple myeloma (MM) is the second most common hematological malignancy with median age of diagnosis between 65–70 years. Since the introduction of multiple novel agents in MM management, survival times of MM patients continue to improve. Longer survival in patients with MM may be a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Lv, Chenglan, Zhou, Min, Xu, Jing-Yan, Chen, Bing, Wan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562683/
https://www.ncbi.nlm.nih.gov/pubmed/36230842
http://dx.doi.org/10.3390/cancers14194919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562683/
https://www.ncbi.nlm.nih.gov/pubmed/36230842
http://dx.doi.org/10.3390/cancers14194919

Ejemplares similares